Although the outcomes of these nilotinib trials will be important in guiding the future of c‐Abl inhibition as a potential strategy for disease modification in PD, there are other c‐Abl inhibitors available that might exhibit better brain penetrance and greater specificity for the c‐Abl kinase that could be more suitable. The gene discussed is ABL1; the disease is Parkinson disease.